Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Transaction Price: $39.05 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest via dividend re-investment.
- Dividend Payment Date: January 6, 2011.
Material Changes
The filing reports an increase in the interest of Mr. D J Phelan in Ordinary share ADRs, totaling 246.15 shares. This change resulted from the re-investment of dividends paid to shareholders. No other material financial changes or comparative period data are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a specific director transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of ADRs held by Mr. D J Phelan following this transaction.
- Confirm the dividend amount per share that was re-invested to generate the 246.15 new ADRs.
- Check for any other concurrent director transactions not detailed in this specific notification.